Risk Management- plan Indehaveren af markedsføringstilladelsen forpligter sig til at udføre studier og yderligere pharmacovigilanceaktiviter, som beskrevet i pharmacovigilanceplanen i overensstemmelse med version 3 af Risk Management- planen (RMP) indeholdt i modul 1. 8. 2. i ansøgningen om markedsføringstilladelse og enhver efterfølgende opdatering af RMP besluttet af CHMP.
Risk Management Plan The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 3 of the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP.